Clinical Trial

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2026-02-10
Trial Details
NCT Number NCT07281976
Lead Sponsor Nanjing Leads Biolabs Co.,Ltd
Collaborators: The First Affiliated Hospital with Nanjing Medical University
Conditions Triple Negative Breast Cancer
Enrollment 220 participants
Start Date 2026-01-27
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-12